Company / Gross Margin
ELITE PHARMACEUTICALS INC /NV/ Gross Margin History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
47.7%
FY2024
5-year range
45.9% / 48.6%
FY2020-FY2024
Trend
+2.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Margin has fluctuated over the past 9 years, ranging from 37.9% in FY2018 to 52.9% in FY2017.
Based on SEC 10-K filings.
47.7% in FY2024 with a 5-year CAGR of +3.4%.
Remained stable around 47.7% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- +1.8pp
- 5-Year Change
- +3.4pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, gross margin increased 2.5% year-over-year.
- Peak gross margin was recorded in FY2017.
- Lowest gross margin in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | 47.7% | +2.5% |
| FY2023 | 46.6% | -4.2% |
| FY2022 | 48.6% | +5.9% |
| FY2021 | 45.9% | -1.9% |
| FY2020 | 46.8% | +5.5% |
| FY2019 | 44.3% | +17.0% |
| FY2018 | 37.9% | -28.4% |
| FY2017 | 52.9% | +36.4% |
| FY2016 | 38.8% | -39.5% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026